Catalent Clarifies Novo Nordisk Ownership of Former Bloomington, Indiana Site
Editor’s note: This statement was updated in June 2026 to reinforce correct references to ownership of the sterile fill-finish site in Bloomington, Indiana, now owned and operated by Novo Nordisk.
Jun 22, 2026 — Catalent, a leading global contract development and manufacturing organization (CDMO), today updated its statement to address ongoing inaccuracies in media coverage regarding the ownership of one of its former sites located in Bloomington, Indiana.
As of December 2024, the Bloomington, Indiana site is no longer part of Catalent’s network. The site is fully owned and operated by Novo Nordisk. This followed Novo Holdings’ acquisition of Catalent in 2024 and the strategic divestiture of the Bloomington, Indiana site and two other sterile fill-finish sites to Novo Nordisk.
Despite Catalent having previously announced and confirmed the ownership changes, reports continue to incorrectly reference the Bloomington, Indiana site as part of Catalent’s network when it is in fact owned and operated by Novo Nordisk. These references are inaccurate and outdated. While legacy naming conventions such as “Catalent Indiana” or “Catalent Indiana, LLC” may still appear in certain regulatory filings, Catalent has no ownership, operational involvement, or oversight of the site.
For clarity, the correct reference for this site is: “the Bloomington, Indiana site, fully owned and operated by Novo Nordisk.” Media are requested to update any references to this site accordingly.
Catalent remains a premier CDMO with nearly 40 facilities worldwide, delivering innovative solutions for pharma, biologics, and consumer health organizations. Catalent’s teams across the globe are committed to driving improved outcomes for customers and patients through an unwavering commitment to service excellence and a patient-first approach.
About Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that Catalent helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. Catalent provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. Catalent tailors end-to-end solutions to meet customers’ needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.
Media Contact:
[email protected]